{
    "info": {
        "nct_id": "NCT04177108",
        "official_title": "A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",
        "inclusion_criteria": "1. Willingness and ability to complete all study-related assessments, including Participant-Reported Outcome (PRO) assessments, in the investigator's judgement.\n2. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1 of Cycle 1.\n3. Life expectancy of at least 6 months.\n4. Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1).\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n6. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs.\n7. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.\n8. Appropriate candidate for paclitaxel monotherapy if tumor programmed death-ligand 1 (PD-L1) status is unknown or non-positive; appropriate candidate for paclitaxel and atezolizumab if tumor PD-L1 status is positive.\n9. Histologically documented triple-negative adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Inability to comply with study and follow-up procedures.\n2. History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.\n3. Severe infection within 4 weeks prior to initiation of study treatment (including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia) as well as those who have received treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment.\n4. Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening).\n5. Known clinically significant history of liver disease consistent with Child-Pugh Class B or C.\n6. Current treatment with anti-viral therapy for hepatitis B virus (HBV).\n7. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure during the study.\n8. Pregnancy or breastfeeding, or intention to become pregnant during the study or within 28 days after the final dose of ipatasertib or (/) placebo, 5 months after the final dose of atezolizumab/placebo, and 6 months after the final dose of paclitaxel whichever occurs later.\n9. New York Heart Association Class II, III, or IV heart failure, left ventricular ejection fraction less than (<) 50 percent (%), or active ventricular arrhythmia requiring medication.\n10. Current unstable angina or history of myocardial infarction within 6 months prior to Day 1 of Cycle 1.\n11. Congenital long QT syndrome or screening QT interval corrected through use Fridericia's formula (QTcF) greater than (>) 480 milliseconds (ms).\n12. Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval.\n13. History or presence of an abnormal ECG that is clinically significant in the investigator's opinion (including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction).\n14. Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease.\n15. Treatment with approved or investigational cancer therapy within 14 days prior to Day 1 of Cycle 1.\n16. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk from treatment complications.\n17. History of or known presence of spinal cord metastases, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments.\n18. Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases.\n19. Known germline breast cancer gene (BRCA)1/2 deleterious mutation, unless the participant is not an appropriate candidate for a poly adenosine diphosphate ribose polymerase (PARP)-inhibitor.\n20. Any previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast.\n21. Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy.\n22. Participants who have received palliative radiotherapy to peripheral sites (e.g., bone metastases) for pain control and whose last treatment was completed 14 days prior to Day 1 of Cycle 1 may be enrolled in the study if they have recovered from all acute, reversible effects (e.g., to Grade 1 or resolved by enrolment).\n23. Uncontrolled pleural effusion, pericardial effusion or ascites.\n24. Uncontrolled tumor-related pain.\n25. Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.\n26. Known hypersensitivity or contraindication to any component of the study treatments, including the paclitaxel excipient, macrogolglycerol ricinoleate.\n27. Grade greater than or equal to (≥) 2 peripheral neuropathy.\n28. History of Type I or Type II diabetes mellitus requiring insulin.\n29. Grade ≥ 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia.\n30. History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).\n31. Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia).\n32. Treatment with strong Cytochrome P450 (CYP)3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.\n33. Prior treatment with an Protein kinase B (Akt) inhibitor.\n34. Active or history of autoimmune disease or immune deficiency.\n35. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n36. Prior allogeneic stem cell or solid organ transplantation.\n37. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with atezolizumab or within 5 months after the final dose of atezolizumab.\n38. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.\n39. Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies.\n40. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.\n41. Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.",
                "criterions": [
                    {
                        "exact_snippets": "For men: agreement to remain abstinent (refrain from heterosexual intercourse)",
                        "criterion": "sexual activity",
                        "requirement": {
                            "requirement_type": "abstinence from heterosexual intercourse",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For men: ... use contraceptive methods",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "use of contraceptive methods",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For men: ... agreement to refrain from donating sperm",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain from donating sperm",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "For men: agreement to remain abstinent (refrain from heterosexual intercourse)",
                                "criterion": "sexual activity",
                                "requirement": {
                                    "requirement_type": "abstinence from heterosexual intercourse",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "For men: ... use contraceptive methods",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "use of contraceptive methods",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "For men: ... agreement to refrain from donating sperm",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain from donating sperm",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Life expectancy of at least 6 months.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Willingness and ability to complete all study-related assessments, including Participant-Reported Outcome (PRO) assessments, in the investigator's judgement.",
                "criterions": [
                    {
                        "exact_snippets": "Willingness ... to complete all study-related assessments",
                        "criterion": "willingness to complete study-related assessments",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ability to complete all study-related assessments",
                        "criterion": "ability to complete study-related assessments",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including Participant-Reported Outcome (PRO) assessments",
                        "criterion": "ability to complete Participant-Reported Outcome (PRO) assessments",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the investigator's judgement",
                        "criterion": "investigator's judgement of willingness and ability",
                        "requirement": {
                            "requirement_type": "investigator's judgement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Willingness ... to complete all study-related assessments",
                                "criterion": "willingness to complete study-related assessments",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "ability to complete all study-related assessments",
                                "criterion": "ability to complete study-related assessments",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "including Participant-Reported Outcome (PRO) assessments",
                                "criterion": "ability to complete Participant-Reported Outcome (PRO) assessments",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "in the investigator's judgement",
                        "criterion": "investigator's judgement of willingness and ability",
                        "requirement": {
                            "requirement_type": "investigator's judgement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1 of Cycle 1.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate hematologic ... function",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within 14 days before the first study treatment on Day 1 of Cycle 1",
                        "criterion": "timing of hematologic and organ function assessment",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before Day 1 of Cycle 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate hematologic ... function",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... organ function",
                                "criterion": "organ function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "within 14 days before the first study treatment on Day 1 of Cycle 1",
                        "criterion": "timing of hematologic and organ function assessment",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before Day 1 of Cycle 1"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs.",
                "criterions": [
                    {
                        "exact_snippets": "For women of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "For women of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "reproductive status",
                            "expected_value": "childbearing potential"
                        }
                    },
                    {
                        "exact_snippets": "agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception",
                        "criterion": "sexual activity and contraception",
                        "requirement": {
                            "requirement_type": "agreement to remain abstinent or use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agreement to refrain from donating eggs",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "agreement to refrain from donating eggs",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "For women of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "For women of childbearing potential",
                                "criterion": "sex and reproductive status",
                                "requirement": {
                                    "requirement_type": "reproductive status",
                                    "expected_value": "childbearing potential"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception",
                        "criterion": "sexual activity and contraception",
                        "requirement": {
                            "requirement_type": "agreement to remain abstinent or use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agreement to refrain from donating eggs",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "agreement to refrain from donating eggs",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1).",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1)",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1)",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1)",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1)",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "1. Inability to comply with study and follow-up procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Inability to comply with study and follow-up procedures.",
                        "criterion": "ability to comply with study and follow-up procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Inability to comply with study and follow-up procedures.",
                    "criterion": "ability to comply with study and follow-up procedures",
                    "requirement": {
                        "requirement_type": "ability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "11. Congenital long QT syndrome or screening QT interval corrected through use Fridericia's formula (QTcF) greater than (>) 480 milliseconds (ms).",
                "criterions": [
                    {
                        "exact_snippets": "Congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "screening QT interval corrected through use Fridericia's formula (QTcF) greater than (>) 480 milliseconds (ms)",
                        "criterion": "QTcF (QT interval corrected by Fridericia's formula)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "screening QT interval corrected through use Fridericia's formula (QTcF) greater than (>) 480 milliseconds (ms)",
                        "criterion": "QTcF (QT interval corrected by Fridericia's formula)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "33. Prior treatment with an Protein kinase B (Akt) inhibitor.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with an Protein kinase B (Akt) inhibitor.",
                        "criterion": "prior treatment with Protein kinase B (Akt) inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment with an Protein kinase B (Akt) inhibitor.",
                        "criterion": "prior treatment with Protein kinase B (Akt) inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Current unstable angina or history of myocardial infarction within 6 months prior to Day 1 of Cycle 1.",
                "criterions": [
                    {
                        "exact_snippets": "Current unstable angina",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current unstable angina",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of myocardial infarction within 6 months prior to Day 1 of Cycle 1",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of myocardial infarction within 6 months prior to Day 1 of Cycle 1",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time_since_event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Current unstable angina",
                                "criterion": "unstable angina",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Current unstable angina",
                                "criterion": "unstable angina",
                                "requirement": {
                                    "requirement_type": "current_status",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "history of myocardial infarction within 6 months prior to Day 1 of Cycle 1",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "history of myocardial infarction within 6 months prior to Day 1 of Cycle 1",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "time_since_event",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Severe infection within 4 weeks prior to initiation of study treatment (including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia) as well as those who have received treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                        "criterion": "severe infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                        "criterion": "severe infection",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks prior to initiation of study treatment"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                        "criterion": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                        "criterion": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks prior to initiation of study treatment"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment",
                        "criterion": "treatment with therapeutic oral or intravenous antibiotics",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment",
                        "criterion": "treatment with therapeutic oral or intravenous antibiotics",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks prior to initiation of study treatment"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                                "criterion": "severe infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                                "criterion": "severe infection",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks prior to initiation of study treatment"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                                "criterion": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                                "criterion": "hospitalization for complications of infection, bacteremia, or severe pneumonia",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks prior to initiation of study treatment"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment",
                                "criterion": "treatment with therapeutic oral or intravenous antibiotics",
                                "requirement": {
                                    "requirement_type": "treatment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation of study treatment",
                                "criterion": "treatment with therapeutic oral or intravenous antibiotics",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2,
                                                "unit": "weeks prior to initiation of study treatment"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "26. Known hypersensitivity or contraindication to any component of the study treatments, including the paclitaxel excipient, macrogolglycerol ricinoleate.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity ... to any component of the study treatments",
                        "criterion": "hypersensitivity to study treatment components",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "contraindication to any component of the study treatments",
                        "criterion": "contraindication to study treatment components",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including the paclitaxel excipient, macrogolglycerol ricinoleate",
                        "criterion": "hypersensitivity or contraindication to paclitaxel excipient (macrogolglycerol ricinoleate)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Known hypersensitivity ... to any component of the study treatments",
                                "criterion": "hypersensitivity to study treatment components",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "contraindication to any component of the study treatments",
                                "criterion": "contraindication to study treatment components",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "including the paclitaxel excipient, macrogolglycerol ricinoleate",
                        "criterion": "hypersensitivity or contraindication to paclitaxel excipient (macrogolglycerol ricinoleate)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. Uncontrolled tumor-related pain.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled tumor-related pain",
                        "criterion": "tumor-related pain",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled tumor-related pain",
                        "criterion": "tumor-related pain",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk from treatment complications.",
                "criterions": [
                    {
                        "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk from treatment complications.",
                        "criterion": "disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                        "requirement": {
                            "requirement_type": "investigator's opinion of contraindication or risk",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk from treatment complications.",
                    "criterion": "disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                    "requirement": {
                        "requirement_type": "investigator's opinion of contraindication or risk",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval.",
                "criterions": [
                    {
                        "exact_snippets": "Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval",
                        "criterion": "medications causing QT/QTc prolongation",
                        "requirement": {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval",
                        "criterion": "medications causing QT/QTc prolongation",
                        "requirement": {
                            "requirement_type": "dose effect",
                            "expected_value": "doses known to cause clinically relevant prolongation of QT/QTc interval"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval",
                        "criterion": "medications causing QT/QTc prolongation",
                        "requirement": {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current treatment with medications used at doses known to cause clinically relevant prolongation of QT/QTc interval",
                        "criterion": "medications causing QT/QTc prolongation",
                        "requirement": {
                            "requirement_type": "dose effect",
                            "expected_value": "doses known to cause clinically relevant prolongation of QT/QTc interval"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "34. Active or history of autoimmune disease or immune deficiency.",
                "criterions": [
                    {
                        "exact_snippets": "Active or history of autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity or history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "immune deficiency",
                        "criterion": "immune deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active or history of autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity or history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "immune deficiency",
                        "criterion": "immune deficiency",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Current treatment with anti-viral therapy for hepatitis B virus (HBV).",
                "criterions": [
                    {
                        "exact_snippets": "Current treatment with anti-viral therapy for hepatitis B virus (HBV)",
                        "criterion": "anti-viral therapy for hepatitis B virus (HBV)",
                        "requirement": {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Current treatment with anti-viral therapy for hepatitis B virus (HBV)",
                    "criterion": "anti-viral therapy for hepatitis B virus (HBV)",
                    "requirement": {
                        "requirement_type": "current treatment",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "18. Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases.",
                "criterions": [
                    {
                        "exact_snippets": "Known central nervous system (CNS) disease",
                        "criterion": "central nervous system (CNS) disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except for treated asymptomatic CNS metastases",
                        "criterion": "CNS metastases",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "treated"
                        }
                    },
                    {
                        "exact_snippets": "except for treated asymptomatic CNS metastases",
                        "criterion": "CNS metastases",
                        "requirement": {
                            "requirement_type": "symptom_status",
                            "expected_value": "asymptomatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known central nervous system (CNS) disease",
                                "criterion": "central nervous system (CNS) disease",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "except for treated asymptomatic CNS metastases",
                                            "criterion": "CNS metastases",
                                            "requirement": {
                                                "requirement_type": "treatment_status",
                                                "expected_value": "treated"
                                            }
                                        },
                                        {
                                            "exact_snippets": "except for treated asymptomatic CNS metastases",
                                            "criterion": "CNS metastases",
                                            "requirement": {
                                                "requirement_type": "symptom_status",
                                                "expected_value": "asymptomatic"
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "37. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with atezolizumab or within 5 months after the final dose of atezolizumab.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment",
                        "criterion": "treatment with a live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to study treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior"
                            }
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for such a vaccine during treatment with atezolizumab",
                        "criterion": "anticipated need for live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to atezolizumab treatment",
                            "expected_value": "during treatment"
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for such a vaccine ... within 5 months after the final dose of atezolizumab",
                        "criterion": "anticipated need for live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to atezolizumab treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "months after final dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment",
                        "criterion": "treatment with a live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to study treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior"
                            }
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for such a vaccine during treatment with atezolizumab",
                        "criterion": "anticipated need for live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to atezolizumab treatment",
                            "expected_value": "during treatment"
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for such a vaccine ... within 5 months after the final dose of atezolizumab",
                        "criterion": "anticipated need for live, attenuated vaccine",
                        "requirement": {
                            "requirement_type": "timing relative to atezolizumab treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "months after final dose"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "39. Known hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                        "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... recombinant human antibodies",
                        "criterion": "hypersensitivity to recombinant human antibodies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                        "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... recombinant human antibodies",
                        "criterion": "hypersensitivity to recombinant human antibodies",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "36. Prior allogeneic stem cell or solid organ transplantation.",
                "criterions": [
                    {
                        "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation.",
                        "criterion": "history of allogeneic stem cell transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation.",
                        "criterion": "history of solid organ transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation.",
                        "criterion": "history of allogeneic stem cell transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior allogeneic stem cell or solid organ transplantation.",
                        "criterion": "history of solid organ transplantation",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. Any previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast.",
                "criterions": [
                    {
                        "exact_snippets": "Any previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast.",
                        "criterion": "previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast.",
                        "criterion": "previous systemic therapy for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "35. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.",
                "criterions": [
                    {
                        "exact_snippets": "History of idiopathic pulmonary fibrosis",
                        "criterion": "idiopathic pulmonary fibrosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                        "criterion": "organizing pneumonia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bronchiolitis obliterans",
                        "criterion": "bronchiolitis obliterans",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "drug-induced pneumonitis",
                        "criterion": "drug-induced pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "idiopathic pneumonitis",
                        "criterion": "idiopathic pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of active pneumonitis on screening chest CT scan",
                        "criterion": "active pneumonitis",
                        "requirement": {
                            "requirement_type": "evidence on screening chest CT scan",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of idiopathic pulmonary fibrosis",
                        "criterion": "idiopathic pulmonary fibrosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                        "criterion": "organizing pneumonia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bronchiolitis obliterans",
                        "criterion": "bronchiolitis obliterans",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "drug-induced pneumonitis",
                        "criterion": "drug-induced pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "idiopathic pneumonitis",
                        "criterion": "idiopathic pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of active pneumonitis on screening chest CT scan",
                        "criterion": "active pneumonitis",
                        "requirement": {
                            "requirement_type": "evidence on screening chest CT scan",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "30. History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).",
                "criterions": [
                    {
                        "exact_snippets": "History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)",
                        "criterion": "inflammatory bowel disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active bowel inflammation (e.g., diverticulitis)",
                        "criterion": "bowel inflammation",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)",
                                "criterion": "inflammatory bowel disease",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "History of or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)",
                                "criterion": "inflammatory bowel disease",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "active bowel inflammation (e.g., diverticulitis)",
                        "criterion": "bowel inflammation",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Known germline breast cancer gene (BRCA)1/2 deleterious mutation, unless the participant is not an appropriate candidate for a poly adenosine diphosphate ribose polymerase (PARP)-inhibitor.",
                "criterions": [
                    {
                        "exact_snippets": "Known germline breast cancer gene (BRCA)1/2 deleterious mutation",
                        "criterion": "germline BRCA1/2 deleterious mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unless the participant is not an appropriate candidate for a poly adenosine diphosphate ribose polymerase (PARP)-inhibitor",
                        "criterion": "appropriateness for PARP-inhibitor",
                        "requirement": {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Known germline breast cancer gene (BRCA)1/2 deleterious mutation",
                    "criterion": "germline BRCA1/2 deleterious mutation",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "unless the participant is not an appropriate candidate for a poly adenosine diphosphate ribose polymerase (PARP)-inhibitor",
                    "criterion": "appropriateness for PARP-inhibitor",
                    "requirement": {
                        "requirement_type": "appropriateness",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "23. Uncontrolled pleural effusion, pericardial effusion or ascites.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled pleural effusion",
                        "criterion": "pleural effusion",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... pericardial effusion",
                        "criterion": "pericardial effusion",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... ascites",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled pleural effusion",
                        "criterion": "pleural effusion",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... pericardial effusion",
                        "criterion": "pericardial effusion",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... ascites",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy.",
                "criterions": [
                    {
                        "exact_snippets": "Unresolved, clinically significant toxicity from prior therapy",
                        "criterion": "toxicity from prior therapy",
                        "requirement": {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        }
                    },
                    {
                        "exact_snippets": "Unresolved, clinically significant toxicity from prior therapy",
                        "criterion": "toxicity from prior therapy",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except for alopecia",
                        "criterion": "alopecia",
                        "requirement": {
                            "requirement_type": "exception to exclusion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "except for ... Grade 1 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "except for ... Grade 1 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "exception to exclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Unresolved, clinically significant toxicity from prior therapy",
                                "criterion": "toxicity from prior therapy",
                                "requirement": {
                                    "requirement_type": "resolution status",
                                    "expected_value": "unresolved"
                                }
                            },
                            {
                                "exact_snippets": "Unresolved, clinically significant toxicity from prior therapy",
                                "criterion": "toxicity from prior therapy",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "or_criteria": [
                                {
                                    "exact_snippets": "except for alopecia",
                                    "criterion": "alopecia",
                                    "requirement": {
                                        "requirement_type": "exception to exclusion",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "except for ... Grade 1 peripheral neuropathy",
                                            "criterion": "peripheral neuropathy",
                                            "requirement": {
                                                "requirement_type": "grade",
                                                "expected_value": {
                                                    "operator": "=",
                                                    "value": 1,
                                                    "unit": "N/A"
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "except for ... Grade 1 peripheral neuropathy",
                                            "criterion": "peripheral neuropathy",
                                            "requirement": {
                                                "requirement_type": "exception to exclusion",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. History or presence of an abnormal ECG that is clinically significant in the investigator's opinion (including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction).",
                "criterions": [
                    {
                        "exact_snippets": "History or presence of an abnormal ECG that is clinically significant in the investigator's opinion",
                        "criterion": "abnormal ECG",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History or presence of an abnormal ECG that is clinically significant in the investigator's opinion",
                        "criterion": "abnormal ECG",
                        "requirement": {
                            "requirement_type": "clinical significance (investigator's opinion)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "complete left bundle branch block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "second- or third-degree heart block",
                        "criterion": "second-degree heart block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "second- or third-degree heart block",
                        "criterion": "third-degree heart block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of prior myocardial infarction",
                        "criterion": "prior myocardial infarction",
                        "requirement": {
                            "requirement_type": "evidence of prior occurrence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History or presence of an abnormal ECG that is clinically significant in the investigator's opinion",
                                "criterion": "abnormal ECG",
                                "requirement": {
                                    "requirement_type": "history or presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "History or presence of an abnormal ECG that is clinically significant in the investigator's opinion",
                                "criterion": "abnormal ECG",
                                "requirement": {
                                    "requirement_type": "clinical significance (investigator's opinion)",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "complete left bundle branch block",
                        "criterion": "complete left bundle branch block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "second- or third-degree heart block",
                        "criterion": "second-degree heart block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "second- or third-degree heart block",
                        "criterion": "third-degree heart block",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of prior myocardial infarction",
                        "criterion": "prior myocardial infarction",
                        "requirement": {
                            "requirement_type": "evidence of prior occurrence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease.",
                "criterions": [
                    {
                        "exact_snippets": "Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day",
                        "criterion": "chronic corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg of prednisone per day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day",
                        "criterion": "chronic corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease",
                        "criterion": "chronic anti-inflammatory corticosteroid or immunosuppressant agent therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "equivalent to > 10 mg of prednisone per day"
                        }
                    },
                    {
                        "exact_snippets": "equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease",
                        "criterion": "chronic anti-inflammatory corticosteroid or immunosuppressant agent therapy",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day",
                                "criterion": "chronic corticosteroid therapy",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mg of prednisone per day"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Requirement for chronic corticosteroid therapy of > 10 mg of prednisone per day",
                                "criterion": "chronic corticosteroid therapy",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease",
                                "criterion": "chronic anti-inflammatory corticosteroid or immunosuppressant agent therapy",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": "equivalent to > 10 mg of prednisone per day"
                                }
                            },
                            {
                                "exact_snippets": "equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease",
                                "criterion": "chronic anti-inflammatory corticosteroid or immunosuppressant agent therapy",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "38. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                "criterions": [
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to chimeric antibodies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to humanized antibodies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to fusion proteins",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to chimeric antibodies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to humanized antibodies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.",
                        "criterion": "severe allergic anaphylactic reactions to fusion proteins",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "32. Treatment with strong Cytochrome P450 (CYP)3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with strong Cytochrome P450 (CYP)3A inhibitors ... within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.",
                        "criterion": "treatment with strong CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "drug-elimination half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with ... strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.",
                        "criterion": "treatment with strong CYP3A inducers",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "drug-elimination half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Treatment with strong Cytochrome P450 (CYP)3A inhibitors ... within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.",
                        "criterion": "treatment with strong CYP3A inhibitors",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "drug-elimination half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with ... strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug.",
                        "criterion": "treatment with strong CYP3A inducers",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "drug-elimination half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "41. Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the study.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment",
                        "criterion": "systemic immunosuppressive medication treatment",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment",
                        "criterion": "systemic immunosuppressive medication treatment",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for systemic immunosuppressive medication during the study",
                        "criterion": "anticipated need for systemic immunosuppressive medication",
                        "requirement": {
                            "requirement_type": "anticipated_need",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for systemic immunosuppressive medication during the study",
                        "criterion": "anticipated need for systemic immunosuppressive medication",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during the study"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment",
                                "criterion": "systemic immunosuppressive medication treatment",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment",
                                "criterion": "systemic immunosuppressive medication treatment",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks prior to initiation of study treatment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "anticipation of need for systemic immunosuppressive medication during the study",
                                "criterion": "anticipated need for systemic immunosuppressive medication",
                                "requirement": {
                                    "requirement_type": "anticipated_need",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "anticipation of need for systemic immunosuppressive medication during the study",
                                "criterion": "anticipated need for systemic immunosuppressive medication",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "during the study"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Participants who have received palliative radiotherapy to peripheral sites (e.g., bone metastases) for pain control and whose last treatment was completed 14 days prior to Day 1 of Cycle 1 may be enrolled in the study if they have recovered from all acute, reversible effects (e.g., to Grade 1 or resolved by enrolment).",
                "criterions": [
                    {
                        "exact_snippets": "Participants who have received palliative radiotherapy to peripheral sites (e.g., bone metastases) for pain control",
                        "criterion": "palliative radiotherapy to peripheral sites for pain control",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "whose last treatment was completed 14 days prior to Day 1 of Cycle 1",
                        "criterion": "time since last palliative radiotherapy",
                        "requirement": {
                            "requirement_type": "minimum time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "if they have recovered from all acute, reversible effects (e.g., to Grade 1 or resolved by enrolment)",
                        "criterion": "recovery from acute, reversible effects of radiotherapy",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": "all acute, reversible effects resolved or Grade 1 by enrolment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants who have received palliative radiotherapy to peripheral sites (e.g., bone metastases) for pain control",
                                "criterion": "palliative radiotherapy to peripheral sites for pain control",
                                "requirement": {
                                    "requirement_type": "history of treatment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "whose last treatment was completed 14 days prior to Day 1 of Cycle 1",
                                "criterion": "time since last palliative radiotherapy",
                                "requirement": {
                                    "requirement_type": "minimum time since last treatment",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "if they have recovered from all acute, reversible effects (e.g., to Grade 1 or resolved by enrolment)",
                                    "criterion": "recovery from acute, reversible effects of radiotherapy",
                                    "requirement": {
                                        "requirement_type": "recovery status",
                                        "expected_value": "all acute, reversible effects resolved or Grade 1 by enrolment"
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.",
                "criterions": [
                    {
                        "exact_snippets": "History of malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other condition that would interfere with enteral absorption",
                        "criterion": "condition interfering with enteral absorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "results in the inability ... to swallow pills",
                        "criterion": "inability to swallow pills",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "results in the ... unwillingness to swallow pills",
                        "criterion": "unwillingness to swallow pills",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "other condition that would interfere with enteral absorption",
                                "criterion": "condition interfering with enteral absorption",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "results in the inability ... to swallow pills",
                                "criterion": "inability to swallow pills",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "results in the ... unwillingness to swallow pills",
                                "criterion": "unwillingness to swallow pills",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "8. Appropriate candidate for paclitaxel monotherapy if tumor programmed death-ligand 1 (PD-L1) status is unknown or non-positive; appropriate candidate for paclitaxel and atezolizumab if tumor PD-L1 status is positive.",
                "criterions": [
                    {
                        "exact_snippets": "Appropriate candidate for paclitaxel monotherapy if tumor programmed death-ligand 1 (PD-L1) status is unknown or non-positive",
                        "criterion": "paclitaxel monotherapy candidacy",
                        "requirement": {
                            "requirement_type": "PD-L1 status",
                            "expected_value": [
                                "unknown",
                                "non-positive"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "appropriate candidate for paclitaxel and atezolizumab if tumor PD-L1 status is positive",
                        "criterion": "paclitaxel and atezolizumab combination therapy candidacy",
                        "requirement": {
                            "requirement_type": "PD-L1 status",
                            "expected_value": "positive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "9. Histologically documented triple-negative adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically documented triple-negative adenocarcinoma of the breast",
                        "criterion": "adenocarcinoma of the breast",
                        "requirement": {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically documented triple-negative adenocarcinoma of the breast",
                        "criterion": "adenocarcinoma of the breast",
                        "requirement": {
                            "requirement_type": "triple-negative",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "locally advanced or metastatic",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "not amenable to resection with curative intent",
                        "criterion": "amenability to resection with curative intent",
                        "requirement": {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "4. Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening).",
                "criterions": [
                    {
                        "exact_snippets": "Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "HIV test result at screening",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known human immunodeficiency virus (HIV) infection (there must be a negative HIV test at screening)",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "HIV test result at screening",
                            "expected_value": "positive"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure during the study.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1",
                        "criterion": "major surgical procedure, open biopsy, or significant traumatic injury",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1",
                        "criterion": "major surgical procedure, open biopsy, or significant traumatic injury",
                        "requirement": {
                            "requirement_type": "reference timepoint",
                            "expected_value": "prior to Day 1 of Cycle 1"
                        }
                    },
                    {
                        "exact_snippets": "anticipation of need for a major surgical procedure during the study",
                        "criterion": "need for a major surgical procedure",
                        "requirement": {
                            "requirement_type": "anticipated during study",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1",
                                "criterion": "major surgical procedure, open biopsy, or significant traumatic injury",
                                "requirement": {
                                    "requirement_type": "time since event",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1",
                                "criterion": "major surgical procedure, open biopsy, or significant traumatic injury",
                                "requirement": {
                                    "requirement_type": "reference timepoint",
                                    "expected_value": "prior to Day 1 of Cycle 1"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "anticipation of need for a major surgical procedure during the study",
                        "criterion": "need for a major surgical procedure",
                        "requirement": {
                            "requirement_type": "anticipated during study",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Pregnancy or breastfeeding, or intention to become pregnant during the study or within 28 days after the final dose of ipatasertib or (/) placebo, 5 months after the final dose of atezolizumab/placebo, and 6 months after the final dose of paclitaxel whichever occurs later.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnancy",
                        "criterion": "pregnancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "intention to become pregnant during the study or within 28 days after the final dose of ipatasertib or (/) placebo, 5 months after the final dose of atezolizumab/placebo, and 6 months after the final dose of paclitaxel whichever occurs later",
                        "criterion": "intention to become pregnant",
                        "requirement": {
                            "requirement_type": "time window after final dose",
                            "expected_value": [
                                "during the study",
                                "within 28 days after the final dose of ipatasertib or placebo",
                                "within 5 months after the final dose of atezolizumab/placebo",
                                "within 6 months after the final dose of paclitaxel (whichever occurs later)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "intention to become pregnant during the study or within 28 days after the final dose of ipatasertib or (/) placebo, 5 months after the final dose of atezolizumab/placebo, and 6 months after the final dose of paclitaxel whichever occurs later",
                        "criterion": "intention to become pregnant",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "27. Grade greater than or equal to (≥) 2 peripheral neuropathy.",
                "criterions": [
                    {
                        "exact_snippets": "Grade greater than or equal to (≥) 2 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Grade greater than or equal to (\u00178) 2 peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Treatment with approved or investigational cancer therapy within 14 days prior to Day 1 of Cycle 1.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with approved or investigational cancer therapy within 14 days prior to Day 1 of Cycle 1.",
                        "criterion": "cancer therapy treatment",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "approved",
                                "investigational"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Treatment with approved or investigational cancer therapy within 14 days prior to Day 1 of Cycle 1.",
                        "criterion": "cancer therapy treatment",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to Day 1 of Cycle 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "9. New York Heart Association Class II, III, or IV heart failure, left ventricular ejection fraction less than (<) 50 percent (%), or active ventricular arrhythmia requiring medication.",
                "criterions": [
                    {
                        "exact_snippets": "New York Heart Association Class II, III, or IV heart failure",
                        "criterion": "New York Heart Association heart failure class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": [
                                "II",
                                "III",
                                "IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "left ventricular ejection fraction less than (<) 50 percent (%)",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "active ventricular arrhythmia requiring medication",
                        "criterion": "active ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "requiring medication",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "40. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.",
                        "criterion": "treatment with systemic immunostimulatory agents",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.",
                        "criterion": "treatment with systemic immunostimulatory agents",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment.",
                        "criterion": "treatment with systemic immunostimulatory agents",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "29. Grade ≥ 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia.",
                "criterions": [
                    {
                        "exact_snippets": "Grade ≥ 2 uncontrolled or untreated hypercholesterolemia",
                        "criterion": "hypercholesterolemia",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade ≥ 2 uncontrolled or untreated hypercholesterolemia",
                        "criterion": "hypercholesterolemia",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled or untreated"
                        }
                    },
                    {
                        "exact_snippets": "Grade ≥ 2 uncontrolled or untreated ... hypertriglyceridemia",
                        "criterion": "hypertriglyceridemia",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade ≥ 2 uncontrolled or untreated ... hypertriglyceridemia",
                        "criterion": "hypertriglyceridemia",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled or untreated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Grade \u00192 uncontrolled or untreated hypercholesterolemia",
                                "criterion": "hypercholesterolemia",
                                "requirement": {
                                    "requirement_type": "grade",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Grade \u00192 uncontrolled or untreated hypercholesterolemia",
                                "criterion": "hypercholesterolemia",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled or untreated"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Grade \u00192 uncontrolled or untreated ... hypertriglyceridemia",
                                "criterion": "hypertriglyceridemia",
                                "requirement": {
                                    "requirement_type": "grade",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Grade \u00192 uncontrolled or untreated ... hypertriglyceridemia",
                                "criterion": "hypertriglyceridemia",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled or untreated"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Known clinically significant history of liver disease consistent with Child-Pugh Class B or C.",
                "criterions": [
                    {
                        "exact_snippets": "Known clinically significant history of liver disease consistent with Child-Pugh Class B or C",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known clinically significant history of liver disease consistent with Child-Pugh Class B or C",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known clinically significant history of liver disease consistent with Child-Pugh Class B or C",
                        "criterion": "liver disease",
                        "requirement": {
                            "requirement_type": "Child-Pugh class",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "25. Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.",
                "criterions": [
                    {
                        "exact_snippets": "Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1",
                        "criterion": "malignancies other than breast cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1",
                        "criterion": "malignancies other than breast cancer",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years prior to Day 1 of Cycle 1"
                            }
                        }
                    },
                    {
                        "exact_snippets": "appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer",
                        "criterion": "appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1",
                                "criterion": "malignancies other than breast cancer",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Malignancies other than breast cancer within 5 years prior to Day 1 of Cycle 1",
                                "criterion": "malignancies other than breast cancer",
                                "requirement": {
                                    "requirement_type": "time frame",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years prior to Day 1 of Cycle 1"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer",
                                    "criterion": "appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer",
                                    "requirement": {
                                        "requirement_type": "presence",
                                        "expected_value": true
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "28. History of Type I or Type II diabetes mellitus requiring insulin.",
                "criterions": [
                    {
                        "exact_snippets": "History of Type I or Type II diabetes mellitus requiring insulin.",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "Type I",
                                "Type II"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "History of Type I or Type II diabetes mellitus requiring insulin.",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of Type I or Type II diabetes mellitus requiring insulin.",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "requiring insulin"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "31. Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia).",
                "criterions": [
                    {
                        "exact_snippets": "pneumonitis",
                        "criterion": "pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "interstitial lung disease",
                        "criterion": "interstitial lung disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "idiopathic pulmonary fibrosis",
                        "criterion": "idiopathic pulmonary fibrosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cystic fibrosis",
                        "criterion": "cystic fibrosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Aspergillosis",
                        "criterion": "Aspergillosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active tuberculosis",
                        "criterion": "active tuberculosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)",
                        "criterion": "history of opportunistic lung infections",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)",
                        "criterion": "history of opportunistic lung infections",
                        "requirement": {
                            "requirement_type": "infection_types",
                            "expected_value": [
                                "pneumocystis pneumonia",
                                "cytomegalovirus pneumonia"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "17. History of or known presence of spinal cord metastases, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments.",
                "criterions": [
                    {
                        "exact_snippets": "History of ... spinal cord metastases",
                        "criterion": "spinal cord metastases",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known presence of spinal cord metastases",
                        "criterion": "spinal cord metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments",
                        "criterion": "spinal cord metastases",
                        "requirement": {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}